Blar i NTNU Open på forfatter "Kallioniemi, Olli"

Viser treff 1-3 av 3

    • Breeze 2.0: An interactive web-tool for visual analysis and comparison of drug response data 

      Potdar, Swapnil; Ianevski, Filipp; Ianevski, Aleksandr; Tanoli, Ziaurrehman; Wennerberg, Krister; Seashore-Ludlow, Brinton; Kallioniemi, Olli; Ostling, Paivi; Aittokallio, Tero Antero; Saarela, Jani (Peer reviewed; Journal article, 2023)
      Functional precision medicine (fPM) offers an exciting, simplified approach to finding the right applications for existing molecules and enhancing therapeutic potential. Integrative and robust tools ensuring high accuracy ...

    • Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors 

      Pietarinen, Paavo O; Eide, Christopher A; Ayuda-Duran, Maria del Pilar; Potdar, Swapnil; Kuusanmäki, Heikki; Andersson, Emma I; Mpindi, John P; Pemovska, Tea; Kontro, Mika; Heckman, Caroline A.; Kallioniemi, Olli; Wennerberg, Krister; Hjorth-Hansen, Henrik; Druker, Brian J; Enserink, Jorrit; Tyner, Jeffrey W.; Mustjoki, Satu; Porkka, Kimmo (Peer reviewed; Journal article, 2017)
      Tyrosine kinase inhibitors (TKI) are the mainstay treatment of BCR-ABL1-positive leukemia and virtually all patients with chronic myeloid leukemia in chronic phase (CP CML) respond to TKI therapy. However, there is limited ...

    • The drug efficacy testing in 3D cultures platform identifies effective drugs for ovarian cancer patients 

      Åkerlund, Emma; Gudoityte, Greta; Moussaud-Lamodière, Elisabeth; Lind, Olina; Bwanika, Henri Colyn; Lehti, Kaisa Irene; Salehi, Sahar; Carlson, Joseph; Wallin, Emelie; Fernebro, Josefin; Östling, Päivi; Kallioniemi, Olli; Joneborg, Ulrika; Seashore-Ludlow, Brinton (Peer reviewed; Journal article, 2023)
      Most patients with advanced ovarian cancer (OC) relapse and progress despite systemic therapy, pointing to the need for improved and tailored therapy options. Functional precision medicine can help to identify effective ...